Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNM001 for RSV Prevention in High-risk Infants
NCT06710925Phase 3Completed
- Sponsor
- Trinomab Pharmaceutical
- Start
- Nov 2024
- Primary completion
- Jul 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in respiratory syncytial virus infection (RSV) comparing TNM001 Arm with Placebo Arm (2 arms). Primary endpoint: Incidence of medically attended lower respiratory tract infection due to RT-PCR confirmed respiratory syncytial virus at 150 days. Started Nov 2024; status: completed.
02
Drugs
TNM001
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT06710925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06710925.